Eli Lilly (NYSE:LLY) touted data this week from a Phase III study evaluating its Humulin R U-500 concentrated insulin delivered via Insulet‘s (NSDQ:PODD) investigational Omnipod U-500 device.
The company reported that people with Type II diabetes taking Humulin R U-500 using the Omnipod device experienced greater A1c reductions and needed less daily insulin compared to adults using multiple daily injections to deliver high doses of insulin.
Eli Lilly, which presented these data at the annual meeting of the American Diabetes Association, developed its Humulin R U-500 product for people with diabetes who are insulin-resistant and need daily doses of more than 200 units of insulin.
“Concentrated insulins are effective treatment options for people with diabetes who have high insulin requirements,” Tom Hardy, senior medical director at Lilly, said in prepared remarks. “People who prefer to use an insulin pump currently do not have an option specifically for Humulin R U-500, which is five-times concentrated. These data show that Humulin R U-500 delivered with this investigational pump may help people better manage their blood sugar levels.”
The company noted that there was no significant difference in symptomatic or severe hypoglycemia between those in the pump group and those using multiple daily injections. Also, researchers observed higher rates of nocturnal hypoglycemia with the Omnipod-Humulin combination compared to multiple daily injections.
“These results show that Humulin R U-500 using Insulet Corporation’s Omnipod technology may help make it easier for people to titrate to their individual needs and improve their blood glucose control,” Dr. Trang Ly, Insulet’s SVP & medical director, added.
Please consider me for any type ll research. The pens hurt and leave lumps under my skin. I just hate them. I inject Levemir and Novo log-R. If 65 million people have this disease we need a better med.